within Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XX05_Lutetium177luVipivotideTetraxetan;

model Lutetium177luVipivotideTetraxetan
  extends Pharmacolibrary.Drugs.ATC.V.V10XX05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V10XX05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lutetium (177Lu) vipivotide tetraxetan (INN; formerly known as lutetium-177 PSMA-617, trade name Pluvicto) is a radioligand therapeutic used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Administered intravenously, it delivers targeted radiation to PSMA-expressing cancer cells. It is approved for clinical use in certain advanced prostate cancers.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult male patients with PSMA-positive metastatic castration-resistant prostate cancer following intravenous administration.</p><h4>References</h4><ol><li><p>Zhang, J, et al., &amp; Baum, RP (2019). Prostate-Specific Membrane Antigen Accumulation in Lower Extremity Lymphedema. <i>Clinical nuclear medicine</i> 44(6) 501–503. DOI:<a href=\"https://doi.org/10.1097/RLU.0000000000002552\">10.1097/RLU.0000000000002552</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30932981/\">https://pubmed.ncbi.nlm.nih.gov/30932981</a></p></li><li><p>Zang, J, et al., &amp; Chen, X (2019). First-in-human study of . <i>European journal of nuclear medicine and molecular imaging</i> 46(1) 148–158. DOI:<a href=\"https://doi.org/10.1007/s00259-018-4096-y\">10.1007/s00259-018-4096-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30090965/\">https://pubmed.ncbi.nlm.nih.gov/30090965</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Lutetium177luVipivotideTetraxetan;
